{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T16:44:14Z","timestamp":1792428254373,"version":"4.5.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,24]],"date-time":"2019-01-24T00:00:00Z","timestamp":1548288000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.vaccine.2019.01.019","type":"journal-article","created":{"date-parts":[[2019,1,26]],"date-time":"2019-01-26T19:33:23Z","timestamp":1548531203000},"page":"1131-1136","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Rabies post-exposure vaccination in 2 visits within a week: A 4-site intradermal regimen"],"prefix":"10.1016","volume":"37","author":[{"given":"M.J.","family":"Warrell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2019.01.019_b0005","doi-asserted-by":"crossref","first-page":"e1847","DOI":"10.1371\/journal.pntd.0001847","article-title":"Million death study collaborators deaths from symptomatically identifiable furious rabies in india: a nationally representative mortality survey","volume":"6","author":"Suraweera","year":"2012","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2019.01.019_b0010","unstructured":"SAGE Working Group on Rabies vaccines and immunoglobulins and the World Health Organization (WHO) Secretariat (2017) Background paper: Proposed revision of the policy on rabies vaccines and rabies immunoglobulins. <http:\/\/www.who.int\/immunization\/sage\/meetings\/2017\/october\/1_Background_paper_WG_RABIES_final.pdf> (accessed 15 September 2018)."},{"key":"10.1016\/j.vaccine.2019.01.019_b0015","unstructured":"WHO. World Health Organization Expert Consultation on Rabies. Third Report. WHO Technical Report Series 1012; 2018. <http:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/272364\/9789241210218-eng.pdf?ua=1> (accessed 11 November 2018)."},{"key":"10.1016\/j.vaccine.2019.01.019_b0020","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1093\/infdis\/156.1.50","article-title":"Rabies preexposure prophylaxis with human diploid cell rabies vaccine: a dose-response study","volume":"156","author":"Fishbein","year":"1987","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2019.01.019_b0025","doi-asserted-by":"crossref","first-page":"3902","DOI":"10.1016\/j.vaccine.2005.03.007","article-title":"Potency requirements of rabies vaccines administered intradermally using the Thai Red Cross regimen: investigation of the immunogenicity of serially diluted purified chick embryo cell rabies vaccine","volume":"23","author":"Beran","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.01.019_b0030","unstructured":"WHO. World Health Organization Expert Consultation on Rabies. Second Report. WHO Technical Report Series 982; 2013. <http:\/\/apps.who.int\/iris\/bitstream\/10665\/85346\/1\/9789240690943_eng.pdf> (accessed 15 September 2018)."},{"key":"10.1016\/j.vaccine.2019.01.019_b0035","first-page":"1","article-title":"One-year immunogenicity kinetics and safety of a purified chick embryo cell rabies vaccine and an inactivated Vero cell-derived Japanese encephalitis vaccine administered concomitantly according to a new, 1-week, accelerated primary series","volume":"23","author":"Cramer","year":"2016","journal-title":"J Travel Med"},{"key":"10.1016\/j.vaccine.2019.01.019_b0040","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1080\/21645515.2015.1048938","article-title":"Comparison of safety and immunogenicity of 2 WHO prequalified rabies vaccines administered by one week, 4 site intra dermal regimen (4-4-4-0-0) in animal bite cases","volume":"11","author":"Narayana","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2019.01.019_b0045","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1086\/649211","article-title":"Postexposure rabies prophylaxis completed in 1 week: preliminary study","volume":"50","author":"Shantavasinkul","year":"2010","journal-title":"Clin Infect Dis."},{"key":"10.1016\/j.vaccine.2019.01.019_b0050","first-page":"33","article-title":"Humoral and cell-mediated immune responses to various economical regimens of purified Vero cell rabies vaccine","volume":"5","author":"Phanuphak","year":"1987","journal-title":"Asian Pac J Allergy Immunol"},{"key":"10.1016\/j.vaccine.2019.01.019_b0055","unstructured":"World Health Organization. WHO recommendations on rabies post-exposure treatment and the correct technique of intradermal immunization against rabies. 1997 WHO\/EMC\/ZOO.96.6 <http:\/\/www.who.int\/rabies\/en\/WHO_recommendation_post_exp_treatment.pdf> (accessed 15 September 2018)."},{"key":"10.1016\/j.vaccine.2019.01.019_b0060","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.biologicals.2011.08.002","article-title":"Antigen content versus volume of rabies vaccines administered intradermally","volume":"39","author":"Dodet","year":"2011","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2019.01.019_b0065","doi-asserted-by":"crossref","first-page":"383870","DOI":"10.4061\/2011\/383870","article-title":"Human rabies in the WHO southeast Asia region: forward steps for elimination","volume":"2011","author":"Gongal","year":"2011","journal-title":"Adv Prev Med"},{"key":"10.1016\/j.vaccine.2019.01.019_b0070","unstructured":"WHO Expert Consultation on rabies. 2005 Tech Rep Ser 931 <http:\/\/apps.who.int\/iris\/bitstream\/10665\/43262\/1\/WHO_TRS_931_eng.pdf?ua=1&ua=1> (accessed 18 September 2018)."},{"key":"10.1016\/j.vaccine.2019.01.019_b0075","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0140-6736(83)90288-X","article-title":"An economical regimen of human diploid cell strain anti-rabies vaccine for post-exposure prophylaxis","volume":"2","author":"Warrell","year":"1983","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2019.01.019_b0080","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/S0140-6736(84)91340-0","article-title":"Multi-site intradermal and multi-site subcutaneous rabies vaccination: improved economical regimens","volume":"1","author":"Warrell","year":"1984","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2019.01.019_b0085","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S0140-6736(85)92367-0","article-title":"Economical multiple-site intradermal immunisation with human diploid- cell-strain vaccine is effective for post-exposure rabies prophylaxis","volume":"1","author":"Warrell","year":"1985","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2019.01.019_b0090","first-page":"145","article-title":"Evaluation of two intradermal vaccination regimens using purified chick embryo cell vaccine for post-exposure prophylaxis of rabies","volume":"14","author":"Madhusudana","year":"2001","journal-title":"Natl Med J India"},{"key":"10.1016\/j.vaccine.2019.01.019_b0095","doi-asserted-by":"crossref","first-page":"e224","DOI":"10.1371\/journal.pntd.0000224","article-title":"A simplified 4-site economical intradermal post- exposure rabies vaccine regimen: a randomised controlled comparison with standard methods","volume":"2","author":"Warrell","year":"2008","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.vaccine.2019.01.019_b0100","doi-asserted-by":"crossref","first-page":"4116","DOI":"10.1016\/j.vaccine.2006.02.036","article-title":"Rabies post-exposure prophylaxis vaccination with purified chick embryo cell vaccine (PCECV) and purified Vero cell rabies vaccine (PVRV) in a four-site intradermal schedule (4-0-2-0-1-1): an immunogenic, cost-effective and practical regimen","volume":"24","author":"Ambrozaitis","year":"2006","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.01.019_b0105","doi-asserted-by":"crossref","unstructured":"Hampson K, Cleaveland S, Briggs D. Evaluation of cost-effective strategies for rabies post-exposure vaccination in low-income countries. PLoS Negl Trop Dis. 2011;5(3):e982. Website comment: Comparison of PEP Vaccination regimens including the proposed 4-\u00adsite ID regimen reduced to a schedule with 3 clinic visits. <http:\/\/journals.plos.org\/plosntds\/article\/comment?id=10.1371\/annotation\/8fb9cbd6-8162-408c-9aac-cb2e662a0d2d>.","DOI":"10.1371\/journal.pntd.0000982"},{"key":"10.1016\/j.vaccine.2019.01.019_b0110","unstructured":"WHO Human and dog rabies prevention and control. Report of the WHO\/Bill & Melinda Gates Foundation Consultation. Annecy, France 7\u20139 October 2009 p 21. <http:\/\/whqlibdoc.who.int\/hq\/2010\/WHO_HTM_NTD_NZD_2010.1_eng.pdf> (accessed on 17 September 2018)."},{"key":"10.1016\/j.vaccine.2019.01.019_b0115","first-page":"1","article-title":"Multisite intradermal vaccination using tissue culture vaccine as an economical prophylactic regimen against rabies","volume":"87","author":"Madhusudana","year":"1988","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.vaccine.2019.01.019_b0120","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1086\/338155","article-title":"Three-year experience with 4-site intradermal booster vaccination with rabies vaccine for postexposure prophylaxis","volume":"33","author":"Tantawichien","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2019.01.019_b0125","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1086\/313610","article-title":"Safety and immunogenicity of preexposure rabies vaccination in children infected with human immunodeficiency virus type 1","volume":"30","author":"Thisyakorn","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2019.01.019_b0130","unstructured":"Deshpande A, Briggs DJ. Rabies vaccination in immunosuppressed patients. In: Rabies Control in Asia. Dodet B, Meslin F-X, Heseltine E, eds.) Paris, John Libbey, 2001; p. 58\u201360."},{"key":"10.1016\/j.vaccine.2019.01.019_b0135","doi-asserted-by":"crossref","first-page":"4350","DOI":"10.1016\/j.vaccine.2009.03.027","article-title":"Antibody response to an eight-site intradermal rabies vaccination in patients infected with Human Immunodeficiency Virus","volume":"27","author":"Sirikwin","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.01.019_b0140","doi-asserted-by":"crossref","first-page":"e122","DOI":"10.1086\/324087","article-title":"Failure of multiple-site intradermal postexposure rabies vaccination in patients with human immunodeficiency virus with Low CD4+ T lymphocyte counts","volume":"33","author":"Tantawichien","year":"2001","journal-title":"Clin Infect Dis"},{"issue":"18","key":"10.1016\/j.vaccine.2019.01.019_b0145","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1097\/QAD.0b013e328331a43b","article-title":"Restoration of the antibody response upon rabies vaccination in HIV-infected patients treated with HAART","volume":"23","author":"Gelinck","year":"2009","journal-title":"AIDS"},{"key":"10.1016\/j.vaccine.2019.01.019_b0150","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1080\/21645515.2015.1076599","article-title":"Safety and immunogenicity of influenza vaccine among HIV-infected adults: conventional vaccine vs. intradermal vaccine","volume":"12","author":"Seo","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2019.01.019_b0155","doi-asserted-by":"crossref","first-page":"7339","DOI":"10.1016\/j.vaccine.2017.10.106","article-title":"Immune responses to intradermal and intramuscular inactivated influenza vaccine among older age group","volume":"35","author":"Boonnak","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.01.019_b0160","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1086\/514737","article-title":"Antibody response after a four-site intradermal booster vaccination with cell-culture rabies vaccine","volume":"28","author":"Tantawichien","year":"1999","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2019.01.019_b0165","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2310\/7060.2002.23189","article-title":"Four-site intradermal postexposure boosters in previously rabies vaccinated subjects","volume":"9","author":"Khawplod","year":"2002","journal-title":"J Travel Med"},{"key":"10.1016\/j.vaccine.2019.01.019_b0170","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1086\/513760","article-title":"Immune response to simulated postexposure rabies booster vaccinations in volunteers who received preexposure vaccinations","volume":"25","author":"Kositprapa","year":"1997","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2019.01.019_b0175","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/j.1708-8305.1999.tb00524.x","article-title":"Immunogenicity of rabies postexposure booster injections in subjects who had previously received intradermal preexposure vaccination","volume":"6","author":"Jaijaroensup","year":"1999","journal-title":"J Travel Med"},{"key":"10.1016\/j.vaccine.2019.01.019_b0180","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/S0140-6736(76)93028-2","article-title":"Human diploid cell strain rabies vaccine. rapid prophylactic immunisation of volunteers with small doses","volume":"1","author":"Turner","year":"1976","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2019.01.019_b0185","unstructured":"Immunisation against infectious disease. London: HMSO;1984."},{"key":"10.1016\/j.vaccine.2019.01.019_b0190","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3390\/tropicalmed2030023","article-title":"Heterogeneity of Rabies vaccination recommendations across Asia","volume":"2","author":"Buchy","year":"2017","journal-title":"Trop Med Infect Dis"},{"key":"10.1016\/j.vaccine.2019.01.019_b0195","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1016\/j.vaccine.2017.02.056","article-title":"Off-label use of vaccines","volume":"35","author":"Neels","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2019.01.019_b0200","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.tmaid.2012.03.004","article-title":"Currently approved post-exposure rabies prophylaxis regimens","volume":"10","author":"Wilde","year":"2012","journal-title":"Travel Med Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2019.01.019_b0205","doi-asserted-by":"crossref","first-page":"629","DOI":"10.20506\/rst.37.2.2829","article-title":"Developments in human rabies prophylaxis","volume":"37","author":"Warrell","year":"2018","journal-title":"Rev Sci Tech Off Int Epiz"},{"key":"10.1016\/j.vaccine.2019.01.019_b0210","article-title":"Intradermal rabies post-exposure prophylaxis can be abridged with no measurable impact on clinical outcome in Cambodia, 2003-2014","author":"Tarantola","year":"2018","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19300738?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X19300738?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,8]],"date-time":"2019-10-08T18:04:43Z","timestamp":1570557883000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X19300738"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":42,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S0264410X19300738"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.01.019","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rabies post-exposure vaccination in 2 visits within a week: A 4-site intradermal regimen","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2019.01.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Author. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}